Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Adaptive Phase 3 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy (WIZARD 201G)
Conditions
Interventions
DSP-7888 Dosing Emulsion
Bevacizumab
Locations
61
United States
University of Alabama at Birmingham
Birmingham, Alabama, United States
Center for Neurosciences
Tucson, Arizona, United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
UCSD- Moores Cancer Center
La Jolla, California, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Cedars Sinai Medical Center
Los Angeles, California, United States
Start Date
December 8, 2017
Primary Completion Date
August 30, 2021
Completion Date
August 30, 2021
Last Updated
November 15, 2023
NCT05969860
NCT02800486
NCT05789394
NCT06934889
NCT06860594
NCT00083512
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions